Market Closed -
Nasdaq
04:00:00 2024-04-30 pm EDT
|
5-day change
|
1st Jan Change
|
4.44
USD
|
+1.25%
|
|
-7.89%
|
-3.69%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16.73
|
13.98
|
5.364
|
6.372
|
6.023
|
-
|
-
|
Enterprise Value (EV)
1 |
16.73
|
13.98
|
5.364
|
6.372
|
6.023
|
6.023
|
6.023
|
P/E ratio
|
-0.21
x
|
0.39
x
|
-0.41
x
|
-1.23
x
|
-0.95
x
|
-1.18
x
|
1.83
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
159
x
|
60.5
x
|
708
x
|
-
|
10.7
x
|
0.26
x
|
EV / Revenue
|
-
|
159
x
|
60.5
x
|
708
x
|
-
|
10.7
x
|
0.26
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
120
|
633
|
1,408
|
1,382
|
1,357
|
-
|
-
|
Reference price
2 |
139.0
|
22.10
|
3.811
|
4.610
|
4.440
|
4.440
|
4.440
|
Announcement Date
|
3/17/21
|
3/30/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0878
|
0.0886
|
0.009
|
-
|
0.563
|
23.41
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-3.126
|
-10.24
|
-5.62
|
-6.353
|
-6.144
|
9.681
|
Operating Margin
|
-
|
-3,562.34%
|
-11,562.49%
|
-62,445.89%
|
-
|
-1,091.3%
|
41.36%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-10.14
|
-5.287
|
-6.353
|
-6.144
|
9.681
|
Net income
1 |
-36.33
|
19.21
|
-10.14
|
-5.287
|
-6.353
|
-6.144
|
9.681
|
Net margin
|
-
|
21,893.75%
|
-11,449.26%
|
-58,739.67%
|
-
|
-1,091.3%
|
41.36%
|
EPS
2 |
-650.0
|
56.10
|
-9.300
|
-3.760
|
-4.680
|
-3.770
|
2.420
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/21
|
3/30/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.0678
|
0.015
|
-
|
0.055
|
0.0186
|
-
|
-
|
0.006
|
0.003
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1.473
|
-1.155
|
-1.791
|
-1.02
|
-6.278
|
-1.113
|
-1.192
|
-1.543
|
-1.772
|
-1.565
|
-1.58
|
-1.596
|
-1.612
|
Operating Margin
|
-2,173.77%
|
-7,699.13%
|
-
|
-1,855.31%
|
-33,752.37%
|
-
|
-
|
-25,719.83%
|
-59,061.33%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-1.791
|
-0.9823
|
-6.216
|
-1.052
|
-1.102
|
-1.454
|
-1.679
|
-1.565
|
-1.58
|
-1.596
|
-1.612
|
Net income
1 |
-3.875
|
-1.155
|
-1.791
|
-0.9823
|
-6.216
|
-1.052
|
-1.102
|
-1.454
|
-1.679
|
-1.565
|
-1.58
|
-1.596
|
-1.612
|
Net margin
|
-5,720.25%
|
-7,699.13%
|
-
|
-1,786.07%
|
-33,417.69%
|
-
|
-
|
-24,232.5%
|
-55,952.33%
|
-
|
-
|
-
|
-
|
EPS
2 |
-41.60
|
-1.800
|
-2.000
|
-0.7000
|
-5.300
|
-0.7000
|
-0.7800
|
-1.020
|
-1.210
|
-1.150
|
-1.160
|
-1.180
|
-1.190
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/13/22
|
8/12/22
|
11/10/22
|
3/31/23
|
5/12/23
|
8/11/23
|
11/14/23
|
3/22/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/21
|
3/30/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Last Close Price
4.44
USD Average target price
30
USD Spread / Average Target +575.68% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.69% | 6.02M | | -3.46% | 102B | | +1.41% | 96.09B | | +2.13% | 22.28B | | -15.84% | 21.4B | | -9.16% | 18.14B | | -39.98% | 17.02B | | -14.65% | 16.09B | | +4.39% | 13.83B | | +31.35% | 11.97B |
Bio Therapeutic Drugs
|